ALK/EGFR-IN-1-d5

ALK/EGFR-IN-1-d5 (Compound (-) -9a) is a deuterated dual-target inhibitor of EGFR and ALK, with an IC50 of 1.08 nM for EGFR and an IC50 of 2.395 nM for ALK. ALK/EGFR-IN-1-d5 inhibits the phosphorylated proteins in the EGFR, ALK, and BRK signaling pathways, blocking the cell cycle, leading to a reduction in mitochondrial membrane potential and cell apoptosis (Apoptosis) . ALK/EGFR-IN-1-d5 also significantly inhibits tumor growth in animal models and demonstrates good safety. ALK/EGFR-IN-1-d5 holds promise for research in the field of cancer treatment[1]

Product Specifications

CAS Number

[2730429-93-1]

UNSPSC

12352005

Target

Anaplastic lymphoma kinase (ALK) ; Apoptosis; BRK; EGFR; Isotope-Labeled Compounds; Mitochondrial Metabolism

Related Pathways

Apoptosis; JAK/STAT Signaling; Metabolic Enzyme/Protease; Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

CN(C)CCN(C1=C(C=C(C(OC)=C1)NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(C([2H])([2H])C([2H])([2H])[2H])=O)=N2)NC(C=C)=O)C

Molecular Formula

C27H29D5ClN7O3S

Molecular Weight

577.15

References & Citations

[1]Nie H, et al. Synthesis of novel deuterated EGFR/ALK dual-target inhibitors and their activity against non-small cell lung cancer. Eur J Med Chem. 2025 Feb 5;283:117146.